Edaravone

CHEMBL290916 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
174.2 g/mol
LogP
1.3
Phase
4

A free radical scavenger used to slow the progression of amyotrophic lateral sclerosis (ALS) and to treat patients following acute ischemic stroke. It protects nerve and brain cells from oxidative damage.

Khối lượng phân tử

174,2000 g/mol

LogP

1,30

TPSA

32,70 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC1=NN(c2ccccc2)C(=O)C1

InChI

InChI=1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3

Molecular Formula

C10H10N2O

HBD / HBA

- / 2

Liên kết có thể quay

1

Nguyên tử nặng

13

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

A free radical scavenger used to slow the progression of amyotrophic lateral sclerosis (ALS) and to treat patients following acute ischemic stroke. It protects nerve and brain cells from oxidative damage.

Yes, Edaravone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL290916. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 4021. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.